Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15697 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Raffaele Napoli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, Unit of Precision Internal Medicine, Federico II University School of Medicine and Institute of Experim…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycated Hemoglobin, Insulin Glargine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the effectiveness of different basal insulins (BI) prescribed as an add‐on to or switch from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy. Materials and Methods Retrospective, real‐world data from electronic medical records of 32 Italian diabetes clinics were used, after propensity score adjustment, to compare effectiveness after 6 months of treatment with second‐ versus first‐generation BI (2BI vs. 1BI) or glargine 300 U/ml versus degludec 100 U/ml (Gla‐300 vs. Deg‐100), when added to (ADD‐ON) or in substitution of (SWITCH) GLP‐1 RA. Only comparisons, including a minimum of 100 patients per group, were performed to ensure adequate robustness of the analyses.
Results
In the ADD‐ON cohort (N = 700), greater benefits of 2BI versus 1BI were found in glycated haemoglobin {HbA1c; estimated mean difference: −0.32% [95% confidence interval (CI) −0.62; −0.02]; p = .04} and fasting blood glucose [FBG; −20.73 mg/dl (95% CI −35.62; −5.84); p = .007]. In the SWITCH cohort (N = 2097), greater benefits of 2BI versus 1BI were found in HbA1c [−0.22% (95% CI −0.42; −0.02); p = .03], FBG [−10.15 mg/dl (95% CI −19.04; −1.26); p = .03], and body weight [−0.67 kg (95% CI −1.30; −0.04); p = .04]. In the SWITCH cohort starting 2BI (N = 688), marked differences in favour of Gla‐300 versus Deg‐100 were documented in HbA1c [−0.89% (95% CI −1.26; −0.52); p < .001] and FBG [−17.89 mg/dl (95% CI −32.45; −3.33); p = .02]. Using propensity score matching as a sensitivity analysis, the benefit on HbA1c was confirmed [−0.55% (95% CI –1.02; −0.08); p = .02]. BI titration was suboptimal in all examined cohorts.
Conclusions
2BI are a valuable option to intensify GLP‐1 RA therapy. Switching to Gla‐300 versus Deg‐100 was associated with greater HbA1c improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, Unit of Precision Internal Medicine, Federico II University School of Medicine and Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, I…
- CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
- Medical Affairs, Sanofi S.r.l., Milan, Italy.
- Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.
ORCID-Profile: Raffaele Napoli, Antonio Nicolucci, Maria Chiara Rossi
Zitieren
APA
Napoli, R., Nicolucci, A., Larosa, M., Rossi, M. C., Candido, R., & RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group (2024). Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15697
Vancouver
Napoli R, Nicolucci A, Larosa M, Rossi MC, Candido R, RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group. Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15697
BibTeX
@article{Napoli2024,
author = {Napoli, Raffaele and Nicolucci, Antonio and Larosa, Monica and Rossi, Maria Chiara and Candido, Riccardo and RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group, RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group},
title = {Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15697}
}
EUVIMED